MediWound

MediWound is a biotechnology company focused on developing, manufacturing, and commercializing products for the treatment of severe burns and chronic wounds.

MediWound’s first product, NexoBrid, is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial- and full-thickness thermal burns within four hours of application without harming viable tissue.

NexoBrid was approved in 2012 by the European Medicines Agency along with the Israeli, Argentinian, South Korean, Russian, and Peruvian Ministries of Health and was granted orphan indication for removal of the eschar, also known as debridement, in adults with deep partial-thickness and full-thickness thermal burns. NexoBrid successfully completed clinical development in hospitalized burn wounds and was launched throughout Europe.

MediWound’s second product, EscharEx, is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid. In two phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds within a few daily applications.

MediWound’s MW005 is a clinical-stage product candidate under development as a topical enzymatic therapy for the treatment of non-melanoma skin cancers.

Primary Sector

Products

Geographic markets

Beyond Air

Treatment Solutions for Respiratory Diseases

Rosetta Genomics

MicroRNA-based Diagnostic Tests for Personalized Medicine

Nyxoah

Hypoglossal Nerve Stimulation Therapy for Obstructive Sleep Apnea

impacX

IoT Connected CPG Products

Pluri

Cell-based Technology Platforms

And much more...